Which Strategies Should Be Implemented in Latin America to Eradicate Hepatitis C Virus by 2030?
Hepatitis C virus (HCV) infection is a global health concern with an estimated worldwide disease prevalence rate of 1%, meaning 71 million individuals are infected.1 In the United States, the estimated prevalence rate is 0.7%, or 7 million individuals.1 Specifically in Latin America, estimations sug...
| Autores: | , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2019 |
| País: | Argentina |
| Institución: | Consejo Nacional de Investigaciones Científicas y Técnicas |
| Repositorio: | CONICET Digital (CONICET) |
| Idioma: | inglés |
| OAI Identifier: | oai:ri.conicet.gov.ar:11336/126656 |
| Acceso en línea: | http://hdl.handle.net/11336/126656 |
| Access Level: | acceso abierto |
| Palabra clave: | HEPATITIS C ERRADICATION LATIN AMERICA TREATMENT https://purl.org/becyt/ford/3.2 https://purl.org/becyt/ford/3 |
| Sumario: | Hepatitis C virus (HCV) infection is a global health concern with an estimated worldwide disease prevalence rate of 1%, meaning 71 million individuals are infected.1 In the United States, the estimated prevalence rate is 0.7%, or 7 million individuals.1 Specifically in Latin America, estimations suggest that only 25% of individuals with suspected HCV infection have been diagnosed, and only 4% received treatment.2 Recent availability in this region of directacting antivirals (DAAs), which are safer and more effective than the interferon-based therapies, may influence treatment paradigms at country levels. |
|---|